Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Posted by Francis Steltz on Aug 10th, 2026

Oliver Luxxe Assets LLC decreased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 46.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 84,217 shares of the company’s stock after selling 72,068 shares during the quarter. Oliver Luxxe Assets LLC’s holdings in Amneal Pharmaceuticals were worth $1,458,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Amneal Pharmaceuticals by 50.0% during the 1st quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock valued at $8,413,000 after acquiring an additional 225,637 shares during the period. Arkadios Wealth Advisors acquired a new stake in Amneal Pharmaceuticals in the first quarter worth $4,165,000. California State Teachers Retirement System increased its stake in Amneal Pharmaceuticals by 37.6% in the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock valued at $2,576,000 after purchasing an additional 56,588 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Amneal Pharmaceuticals by 33.7% during the first quarter. Royal Bank of Canada now owns 12,646 shares of the company’s stock valued at $157,000 after purchasing an additional 3,191 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Amneal Pharmaceuticals by 10.5% during the first quarter. The Manufacturers Life Insurance Company now owns 88,007 shares of the company’s stock valued at $1,094,000 after purchasing an additional 8,347 shares during the period. Institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AMRX shares. The Goldman Sachs Group restated a “buy” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Barclays increased their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. UBS Group raised their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.67.

View Our Latest Research Report on AMRX

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $18.14 on Monday. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a one year low of $8.21 and a one year high of $19.26. The company has a market cap of $5.79 billion, a PE ratio of 37.02 and a beta of 1.27. The firm has a 50-day moving average of $16.79 and a 200-day moving average of $14.45.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. As a group, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

About Amneal Pharmaceuticals

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.